ReviewCurrent drug safety2026
Self-Micro-Emulsifying Drug Delivery Systems: In-Depth Review on Enhancing Solubility and Therapeutic Efficacy of BCS Class II Drugs.
Review in Current drug safety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of self-micro-emulsifying drug delivery system (SMEDDS) has revolutionized pharmaceutical formulation by providing an advanced method of increasing medication bioavailability and therapeutic effectiveness. The systems encapsulate hydrophobic drugs in nanoscale droplets and enable them to be soluble and stable in water via the spontaneous formation of oil in water emulsions when gently agitated. Using SMEDDS, pharmaceuticals can be extended to offer enhanced therapeutic potential, and new medicines can be developed that were previously impossible to develop due to their bioavailability limitations. They are versatile and user-friendly, helping to reduce pill burden and improve comfort, which can support better compliance and outcomes. Challenges such as formulation stability and regulatory compliance have been identified in various literature as hurdles for adopting SMEDDS in clinical applications. To address these gaps, this work covers multiple components used in SMEDDS, their classification, formulation methods, characterization, and their advantages and disadvantages. In order to expedite the application of Self-Emulsifying Drug Delivery Systems (SEDDS) in pharmaceutical research, it offers comprehensive statistics on all the necessary aspects of self-micro-emulsifying formulations. Several emulsion-based technologies suitable for edible delivery methods in the drug, cosmetics, and other industries are described. These consist of filled hydrogel particles, solid lipid particles, multiple emulsions, multilayer emulsions, and traditional emulsions.
Indexed as
Identifiers
40143393What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.